Department of Neurodegeneration, Center of Neurology, Hertie Institute for Clinical Brain Research, University of Tuebingen, Tuebingen, Germany.
Mov Disord. 2011 Jan;26(1):176-81. doi: 10.1002/mds.23358. Epub 2010 Sep 14.
Reduced (GSH(R)) but not oxidized glutathione (GSSG) has been shown to be dramatically altered in the substantia nigra (SN) of Lewy body disease (LBD) patients post mortem; but up to now, there is no convincing evidence that these changes can be monitored in vivo. We investigated GSH(R) and GSSG in rapidly processed cerebrospinal fluid (CSF) and plasma samples of 80 LBD and 35 control subjects and detected reduced CSF GSH(R) levels in LBD subjects. The reduction was negatively associated with age but not with disease-associated parameters. Plasma GSH(R), CSF GSSG, and plasma GSSG levels did not significantly differ between the groups. Our findings confirm the results from neuropathologic studies, which demonstrated an alteration of the glutathione system in LBD. We hypothesize that alterations of the glutathione system occur in a very early stage of the disease or may even represent a risk marker for LBD.
还原型谷胱甘肽(GSH(R))而非氧化型谷胱甘肽(GSSG)在路易体病(LBD)患者死后的黑质(SN)中明显改变,但到目前为止,尚无令人信服的证据表明可以在体内监测到这些变化。我们研究了 80 名 LBD 和 35 名对照受试者的快速处理的脑脊液(CSF)和血浆样本中的 GSH(R)和 GSSG,并在 LBD 受试者中检测到还原型 CSF GSH(R)水平降低。这种降低与年龄呈负相关,但与疾病相关参数无关。组间血浆 GSH(R)、CSF GSSG 和血浆 GSSG 水平无显著差异。我们的发现证实了神经病理学研究的结果,该研究表明 LBD 中谷胱甘肽系统发生了改变。我们假设谷胱甘肽系统的改变发生在疾病的早期阶段,甚至可能代表 LBD 的风险标志物。